These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30422039)

  • 21. Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.
    Al-Samkari H
    Drugs Today (Barc); 2018 Nov; 54(11):647-655. PubMed ID: 30539164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis.
    Lindquist I; Olson SR; Li A; Al-Samkari H; Jou JH; McCarty OJT; Shatzel JJ
    Platelets; 2022 Jan; 33(1):66-72. PubMed ID: 33459573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States.
    Dieterich DT; Bernstein D; Flamm S; Pockros PJ; Reau N
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1311-1322. PubMed ID: 32813292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of avatrombopag for the treatment of thrombocytopenia.
    Virk ZM; Kuter DJ; Al-Samkari H
    Expert Opin Pharmacother; 2021 Feb; 22(3):273-280. PubMed ID: 33095074
    [No Abstract]   [Full Text] [Related]  

  • 26. Moving towards a new era in the management of chronic immune thrombocytopenia.
    Wadenvik H; Olsson B
    Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial.
    Deng J; Hu H; Huang F; Huang C; Huang Q; Wang L; Wu A; Yang J; Qin D; Zou W; Wu J
    Front Pharmacol; 2021; 12():704093. PubMed ID: 34393785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.
    Tarantino MD; Bakshi KK; Brainsky A
    Platelets; 2014; 25(1):55-61. PubMed ID: 23402314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease.
    Yoshida M; Tateishi R; Hiroi S; Hongo Y; Fujiwara M; Kitanishi Y; Iwasaki K; Takeshima T; Igarashi A
    Adv Ther; 2022 Jan; 39(1):379-390. PubMed ID: 34748184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelets in liver disease, cancer and regeneration.
    Kurokawa T; Ohkohchi N
    World J Gastroenterol; 2017 May; 23(18):3228-3239. PubMed ID: 28566882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
    Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    J Gastroenterol; 2019 Feb; 54(2):171-181. PubMed ID: 30105510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia.
    Aref S; Mabed M; Selim T; Goda T; Khafagy N
    Hematology; 2004; 9(5-6):351-6. PubMed ID: 15763973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review.
    Van Remoortel H; Scheers H; Avau B; Georgsen J; Nahirniak S; Shehata N; Stanworth SJ; De Buck E; Compernolle V; Vandekerckhove P
    Pharmacoeconomics; 2023 Aug; 41(8):869-911. PubMed ID: 37145291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.
    Newland A
    Semin Hematol; 2007 Oct; 44(4 Suppl 5):S35-45. PubMed ID: 18096471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombocytopenia associated with chronic liver disease.
    Afdhal N; McHutchison J; Brown R; Jacobson I; Manns M; Poordad F; Weksler B; Esteban R
    J Hepatol; 2008 Jun; 48(6):1000-7. PubMed ID: 18433919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use.
    Evangelista ML; Amadori S; Stasi R
    Curr Drug Discov Technol; 2007 Oct; 4(3):162-73. PubMed ID: 17985999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the liver in the production of thrombopoietin compared with erythropoietin.
    Jelkmann W
    Eur J Gastroenterol Hepatol; 2001 Jul; 13(7):791-801. PubMed ID: 11474308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lusutrombopag: First Global Approval.
    Kim ES
    Drugs; 2016 Jan; 76(1):155-8. PubMed ID: 26666417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence.
    Qureshi K; Patel S; Meillier A
    Int J Hepatol; 2016; 2016():1802932. PubMed ID: 27800187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum thrombopoietin in chronic liver disease: relation to severity of the disease and spleen size.
    Freni MA; Spadaro A; Ajello A; Barbaro E; Scaffidi M; Alessi N; Resta ML; Ferraù O
    Hepatogastroenterology; 2002; 49(47):1382-5. PubMed ID: 12239947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.